Published by:  World Anti-Doping Agency  Stock Exchange Tower 800 Place Victoria (Suite 1700) PO Box 120 Montreal, Quebec  Canada H4Z 1B7  www.wada-ama.org   Tel:       +1 514 904 9232 Fax:      +1 514 904 8650 E-mail:  code@wada-ama.org            ISRM – January 2023  Page 3 of 54 TABLE OF CONTENTS   PART ONE: INTRODUCTION, CODE  PROVISIONS, INTERNATIONAL STANDARD PROVISIONS AND DEFINITIONS ............................................... ............................................................... .................... 5 1.0 INTRODUCTION AND SCOPE .................................... ............................................................... .... 5 2.0 CODE  PROVISIONS ................................................... ............................................................... ..... 5 3.0 DEFINITIONS AND INTERPRETATION ............................ ............................................................. 6  3.1 Defined Terms from the 2021 Code  that are Used in the International Standard  for Results Management  .............................................................. ............................................................. 6  3.2 Defined Terms from the International Standard  for Testing  and Investigations .................... 13 3.3 Defined Terms from the International Standard  for Laboratories .......................................... 13  3.4 Defined Term from the International Standard  for Therapeutic Use Exemptions  .................. 14 3.5 Defined Term from the International Standard for Protection of Privacy and Personal Information  .............................................................. .............................................................. 14 3.6 Defined Terms Specific to the International Standard  for Results Management  ................... 15 3.7 Interpretation ............................................ ............................................................... .............. 16 PART TWO:  RESULTS MANAGEMENT  – GENERAL PRINCIPLES ......................................... ........ 17 4.0 GENERAL PRINCIPLES ........................................ ............................................................... ........ 17 4.1 Confidentiality of Results Management  .............................................................. ................... 17 4.2 Timeliness ................................................ ............................................................... .............. 17 PART THREE:  RESULTS MANAGEMENT  – PRE-ADJUDICATION ........................................... ....... 18 5.0 FIRST RESULTS MANAGEMENT  PHASE ........................................................ .......................... 18 5.1 Adverse Analytical Findings  .............................................................. .................................... 18 5.2 Atypical Findings  .............................................................. ..................................................... 23 5.3 Matters Not Involving an Adverse Analytical Finding or Atypical Finding  .............................. 24 5.4 Decision Not to Move Forward .............................. ............................................................... .